- Email: [email protected]
Continuing Medical Education examination: Mechanisms of immunotherapy
Reviews and feature articles
Continuing Medical Education examination Mechanisms of immunotherapy Instructions for category 1 Continuing Medical Education credit The American Academy of Allergy, Asthma and Immunology is accredited as a provider of Continuing Medical Education (CME) by the Accreditation Council for Continuing Medical Education. Test ID no.: mai0034 Contact hours: 1.0 Expiration date: May 31, 2005 Category 1 credit can be earned by reading the text material and taking this CME examination online. For complete instructions, visit the Journal’s Web site at www.mosby.com/jaci.
Learning objectives: ‘‘Mechanisms of immunotherapy’’ 1. 2. 3. 4.
To To To To
become familiarized with changes in antibody and T-cell responses that accompany immunotherapy. appreciate the potential significance of IL-10 as a regulatory cytokine in the context of immunotherapy. introduce the concept of regulatory T cells as modulators of immune responses. understand the clinical and immunologic rationale for the development of new immunotherapy vaccines.
CME items Question 1. Immunotherapy has been associated with all of the following except — A. suppression of early and late responses to allergen challenge. B. improvement in symptoms for 6 to 12 months after treatment cessation, followed by relapse. C. reduced progression from allergic rhinitis to asthma in children. D. protection from anaphylaxis to bee stings. Question 2. Responses to immunotherapy include — A. reductions in serum IgE concentrations to undetectable levels. B. increases in IL-4 production by T cells. C. production of blocking allergen-specific IgG4 antibodies. D. local and systemic reactions due to cross-linking of surface bound IgE on eosinophils.
J ALLERGY CLIN IMMUNOL
Question 3. IL-10 — A. stimulates IgE production by B cells. B. is produced after immunotherapy with house dust mite and pollen but not bee venom allergen vaccines. C. affects cellular and humoral responses to allergen. D. is produced by CD8+CD25+ T cells Question 4. Novel immunotherapy strategies currently being explored include — A. use of bacterial derived RNA as an adjuvant. B. recombinant modified allergens that act on mast cells but not on T cells. C. bacterial derived peptides that stimulate TH1 responses. D. use of immunostimulatory sequences of DNA as an adjuvant.
June 2004 1035
Continuing Medical Education examination Mechanisms of immunotherapy Instructions for category 1 Continuing Medical Education credit The American Academy of Allergy, Asthma and Immunology is accredited as a provider of Continuing Medical Education (CME) by the Accreditation Council for Continuing Medical Education. Test ID no.: mai0034 Contact hours: 1.0 Expiration date: May 31, 2005 Category 1 credit can be earned by reading the text material and taking this CME examination online. For complete instructions, visit the Journal’s Web site at www.mosby.com/jaci.
Learning objectives: ‘‘Mechanisms of immunotherapy’’ 1. 2. 3. 4.
To To To To
become familiarized with changes in antibody and T-cell responses that accompany immunotherapy. appreciate the potential significance of IL-10 as a regulatory cytokine in the context of immunotherapy. introduce the concept of regulatory T cells as modulators of immune responses. understand the clinical and immunologic rationale for the development of new immunotherapy vaccines.
CME items Question 1. Immunotherapy has been associated with all of the following except — A. suppression of early and late responses to allergen challenge. B. improvement in symptoms for 6 to 12 months after treatment cessation, followed by relapse. C. reduced progression from allergic rhinitis to asthma in children. D. protection from anaphylaxis to bee stings. Question 2. Responses to immunotherapy include — A. reductions in serum IgE concentrations to undetectable levels. B. increases in IL-4 production by T cells. C. production of blocking allergen-specific IgG4 antibodies. D. local and systemic reactions due to cross-linking of surface bound IgE on eosinophils.
J ALLERGY CLIN IMMUNOL
Question 3. IL-10 — A. stimulates IgE production by B cells. B. is produced after immunotherapy with house dust mite and pollen but not bee venom allergen vaccines. C. affects cellular and humoral responses to allergen. D. is produced by CD8+CD25+ T cells Question 4. Novel immunotherapy strategies currently being explored include — A. use of bacterial derived RNA as an adjuvant. B. recombinant modified allergens that act on mast cells but not on T cells. C. bacterial derived peptides that stimulate TH1 responses. D. use of immunostimulatory sequences of DNA as an adjuvant.
June 2004 1035